Role of quantitative hepatitis B core antibody levels in predicting significant liver inflammation in chronic hepatitis B patients with normal or near‐normal alanine aminotransferase levels

• Published in: Hepatology research 2018-02, Vol.48 (3), p.E133-E145
• Main Authors: Li, Jing, Zhang, Tian‐Ying, Song, Liu‐Wei, Qi, Xun, Yu, Xue‐Ping, Li, Fa‐Hong, Zhou, Pu, Qin, Yan‐Li, Yang, Lin, Zhao, Jing‐Hua, Mao, Ri‐Cheng, Zhang, Yong‐Mei, Wang, Jin‐Yu, Yang, Fei‐Fei, Zhu, Hao‐Xiang, Yang, Si‐Si, Huang, Yu‐Xian, Yuan, Quan, Zhang, Jun, Zhang, Ji‐Ming, Xia, Ning‐Shao
• Format: Article
• Language: English
• Subjects: Alanine; Alanine transaminase; Biopsy; chronic HBV infection; Hepatitis; Hepatitis B; hepatitis B virus; Inflammation; Interferon; Liver; non‐invasive marker; quantitative anti‐HBc
• ISSN: 1386-6346; 1872-034X
• DOI: 10.1111/hepr.12937

Aim Chronic hepatitis B (CHB) patients with normal alanine aminotransferase (ALT) levels are not free from significant hepatic lesions. Recently, there has been an improved understanding of the clinical significance of quantitative hepatitis B core antibody levels (qAnti‐HBc) during CHB management. In this cross‐sectional study, we evaluated the utility of qAnti‐HBc in identifying significant liver inflammation in CHB patients. Methods A total of 469 patients (training set, n = 363; validation set, n = 106) who underwent liver biopsy (LB) were included. The qAnti‐HBc levels were quantified and the relationship between histology and serum markers was systematically analyzed. Results In the training set, qAnti‐HBc levels were found to have significant diagnostic value for moderate to severe liver inflammation (≥G2) in all patients (area under the receiver operating characteristic curve [AUROC] = 0.768; 95% confidence interval [CI], 0.721–0.810; P